Pablo Legorreta (investor - Angel Investor)

Mexico
See something wrong or missing? Let us know

Pablo Legorreta is a former Wall Street investment banker from a prominent Mexican family who keeps a low profile. He is founder & CEO of Royalty Pharma, the industry leader in acquiring revenue-producing intellectual property, with over $15 billion in royalty assets either indirectly, when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors) or directly, when it partners with life sciences companies to co-develop and co-fund products in late-stage human clinical trials.

Average round investment:67M USD
Average number per year:1.0
Distribution: 2018 (1)
Portfolio companies: Sweden ITBMed
Mostly invests in: Sweden Sweden (1) Biotech (1)

1 tracked investments in:


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Pablo Legorreta

Name Criteria
United States General Atlantic
71%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 1.8
Finland Sampo Group
70%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 2.5
United Arab Emirates Mubadala Capital
68%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Sweden
  • Average number of deals per year: 3.3
United States Venrock Healthcare Capital Partners
68%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
China GT Healthcare Capital
68%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
United States Foresite Capital
68%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
United States Viking Global Investors
68%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
Germany Evotec AG
68%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
United States Cormorant Asset Management
68%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
United States venBio Partners
68%
  • Range for average deal size: 50M+ USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
Top